Analysis of Graft Function Following Autologous Islet Transplantation

A total of 100 subjects will be enrolled in this study; 85 subjects will be enrolled from patients who are scheduled for TP-AIT and 15 subjects will be for TP alone at Baylor University Medical Center at Dallas or Baylor All Saints Medical Center at Fort Worth. The patients who are enrolled in a clinical study, named 'A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet auto-transplantation (REP0112, IND# 117390)', can be enrolled in this study.

Inclusion criteria

• Patients with chronic pancreatitis and who are scheduled for TP alone or TP-AIT
• Patients aged 18 or older
• Patients are able and willing to attend required follow-up visits at Baylor

Exclusion criteria

• Patients who are unable/unwilling to attend follow-up visits at Baylor
• For TP-AIT subjects: Patients who have advanced stage of chronic pancreatitis. The principal investigator or co-investigators carefully review the medical charts, laboratory results and radiology department reports and determine the suitability for this study.